RxDoctor Payments Data

Victor Mwansa, MD

Interventional Cardiology · Marion, ILNPI 1811194244

Payments from drug & device makers

$17,890in general payments, 2019–2025

Across 409 payments — averaging $43.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Abbott$5K
  • Siemens Medical Solutions USA, Inc.$828
  • Abiomed$759
  • Johnson & Johnson$694
  • Philips North America LLC$688
  • plus $5K from 28 others

What the payments were for

  • Grants$951%
  • Travel & lodging$8,59748%
  • Food & beverage$9,01550%
  • Education$1831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,890 in reported general payments places this provider in the 65th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$352,507
Medicare patients
1,136
Services billed
4,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban311$293,921
JardianceEmpagliflozin94$86,437
EntrestoSacubitril/Valsartan84$77,821
XareltoRivaroxaban81$70,911
BrilintaTicagrelor73$47,652
FarxigaDapagliflozin Propanediol13$17,286
Dofetilide45$8,152
Ranolazine ErRanolazine66$5,332
Nifedipine ErNifedipine97$3,098
Metoprolol Succinate161$2,085
Amiodarone Hcl114$1,968
Atorvastatin Calcium204$1,948
Carvedilol246$1,681
ClopidogrelClopidogrel Bisulfate158$1,523
Isosorbide Mononitrate ErIsosorbide Mononitrate90$1,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$680$293,921311 claims
Boehringer IngelheimJardiance$546$86,43794 claims
NovartisEntresto$451$77,82184 claims
Johnson & JohnsonXarelto$694$70,91181 claims
AstraZenecaBrilinta, Farxiga$76$64,93986 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Marion

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →